Trials / Unknown
UnknownNCT04974957
Study of SHR-1701 Plus BP102 in Subjects With Selected Solid Tumors
A Multicenter, Open-Label, Phase Ib/II Trial of SHR-1701 Plus BP102 in Subjects With Selected Solid Tumors
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 71 (estimated)
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study was to assess the safety,efficacy and pharmacokinetic when combining SHR-1701 and BP102 in participants with advanced or metastatic non-squamous non-small cell lung cancer. To explore the immunogenicity of SHR-1701 and the relationship between corresponding biomarkers and therapeutic effect.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-1701；BP102 | Drug: SHR-1701 IV infusion Drug: BP102 IV infusion |
Timeline
- Start date
- 2021-08-30
- Primary completion
- 2022-02-28
- Completion
- 2022-08-30
- First posted
- 2021-07-23
- Last updated
- 2021-07-23
Source: ClinicalTrials.gov record NCT04974957. Inclusion in this directory is not an endorsement.